Medical sector’s Cellectis’s (NASDAQ:CLLS) Hold rating Reiterated by Robert W. Baird –

0
87

Cellectis (NASDAQ:CLLS)‘s stock had its Hold rating Reiterated by analysts at Robert W. Baird – 3 stars in a research report issued to clients and investors. A price-to-earnings ratio of #N/A, market cap of 412.0M and a beta of 2.35.  Cellectis has a twelve month low $8.72 of  and a twelve month high of $34.71.

Shares of Cellectis traded up $0.13 on friday, reaching $10.83. 40 shares of the stock traded hands, compared to its average volume of 234144. Shares of Cellectis at close on friday were at $10.83. The firm’s 50 day moving average is $13.07 and its 200 day moving average is 18.Cellectis  has a 12 month low of $10.45 and a 12 month high of $34.71. While on yearly highs and lows, Cellectis’s today has traded high as $10.87 and has touched $10.45 on the downward trend. See More Analyst Rating at: RATING

Cellectis (NASDAQ:CLLS) Moving Average Technical Analysis

5 day Moving Average is 9.87 And 5 day price change is 1.72 (18.88%)  with average volume for 5 day average is 379,160. While technical analysis for average 20 days shows significant difference, 20 day moving average is  11.98 and 20 day price change is -3.6 (-24.95%) and average 20 day moving volume is 305,075. 50 day moving average is 13.07  and 50 day price change is -2.88 ( -21.01%)  and with average volume for 50 days is : 210,002. 200 day moving average is 18  and 200 day price change is -18.58 (-63.18%)  and with average volume for 200 days is : 292,909.

See More Analyst Rating at: RATING

Cellectis Earnings and What to expect: 

Cellectis last released its quarterly earnings results on August 5th, 2021. The biotechnology company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.13. The firm earned $14.62 million during the quarter, compared to the consensus estimate of $12.43 million. Cellectis has generated ($1.91) earnings per share over the last year (($2.82) diluted earnings per share). Earnings for Cellectis are expected to grow in the coming year, from ($2.56) to ($2.16) per share. Cellectis has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Cellectis are expected to grow in the coming year, from ($2.56) to ($2.16) per share. The P/E ratio of Cellectis is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cellectis is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cellectis has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Other owners latest trading in Cellectis :

  • On 8/23/2021 shares held by Morgan Stanley were 114,860 which equates to market value of $1.78M and appx 0.00% owners of Cellectis
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 28,930 which equates to market value of $0.45M and appx 0.00% owners of Cellectis
  • On 8/17/2021 shares held by Capital Impact Advisors LLC were 214,205 which equates to market value of $3.31M and appx 1.10% owners of Cellectis
  • In total Institutional ownership equates to Institutional Ownership Percentage: 35.71% for Cellectis

See More Analyst Rating at: RATING